四国拉丁美洲产前检查时机与频率对孕产妇RSV疫苗接种机会的影响
该回顾性横断面分析纳入玻利维亚、厄瓜多尔、洪都拉斯和乌拉圭八家三级医院的37,604名15-45岁、2023年至少一次产前检查并单胎活产的妇女,评估产前检查时机与频率相对于孕产妇RSV疫苗接种推荐窗口的匹配程度。结果显示63.5%的妇女在PAHO推荐窗口(32-36周)至少有一次产前检查,91.4%在WHO推荐窗口(≥28周)至少有一次,中位产前检查次数为5次(范围5-8次)。较早开始产前检查与更多就诊次数相关,提示在拉美地区实现孕产妇RSV疫苗高覆盖具有潜力,但较晚或较少的产前检查可能限制窄窗口疫苗的可及性。
要点
- 在四个拉美国家中,63.5%的妇女在PAHO推荐孕周(32-36周)内至少有一次产前检查。
- 91.4%的妇女在WHO推荐孕周(≥28周)内至少有一次产前检查。
- 中位产前检查次数为5次,较早开始产前检查与更多就诊次数相关。
核心结论
- 在拉美四国,孕产妇RSV疫苗覆盖潜力较大,尤其依据WHO较宽推荐窗口时。
- 产前检查开始较晚或次数较少时,较窄的疫苗推荐窗口可能限制可达到的覆盖率。
研究设计与样本
- 回顾性横断面分析,使用玻利维亚、厄瓜多尔、洪都拉斯和乌拉圭八家三级医院的围产期信息系统数据。
- 纳入2023年至少一次产前检查、15-45岁、在研究机构单胎活产的妇女,共37,604名。
- RSV疫苗接种资格依据PAHO(32-36周)和WHO(≥28周)推荐定义。
主要发现
- 产前检查开始的中位孕周为12周,范围从乌拉圭10周到厄瓜多尔15周。
- 63.5%的妇女在PAHO窗口(32-36周)至少有一次产前检查,国家间从洪都拉斯53.6%到乌拉圭82.3%。
- 91.4%的妇女在WHO窗口(≥28周)至少有一次产前检查。
- 中位产前检查次数为5次,范围从洪都拉斯5次到乌拉圭8次。
- 较早开始产前检查与更高的就诊次数相关。
关键数值与推荐
- PAHO推荐孕产妇RSV疫苗接种孕周为32-36周。
- WHO推荐孕产妇RSV疫苗接种孕周为≥28周。
临床怎么用
- 在拉美地区规划孕产妇RSV疫苗实施时,应参考产前检查时机与频率数据评估可达覆盖。
- 加强早期产前检查参与和免疫咨询可能增加疫苗接种机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Latin American and Caribbean region (LAC) has historically been an early adopter of new vaccines, including the recently introduced maternal vaccine to protect infants against respiratory syncytial virus (RSV). Since maternal RSV vaccination requires gestational age (GA)-specific administration, antenatal care (ANC)-based delivery feasibility depends on ANC visit timing and frequency. We assessed ANC attendance relative to recommended vaccination windows in four LAC countries to inform planning for maternal RSV vaccine implementation and future maternal immunization programs. METHODS: We conducted a retrospective, cross-sectional analysis from Perinatal Information System data across eight tertiary facilities in Bolivia, Ecuador, Honduras, and Uruguay. Women 15-45 years old with ≥1 ANC visit in 2023 and a live, singleton birth at a study facility were included. GA per visit was extracted or derived from last menstrual period or birth data. We defined RSV vaccination eligibility according to Pan American Health Organization (PAHO) (32-36 weeks) and World Health Organization (WHO) (≥ 28 weeks) recommendations. Descriptive analyses summarized ANC initiation, visit timing, and the proportion of women attending visits within eligibility windows. RESULTS: We included 37,604 women. The median GA at ANC initiation was 12 weeks, ranging from 10 weeks (Uruguay) to 15 weeks (Ecuador). Overall, 63.5% of women attended at least one ANC visit during the PAHO window, with country-specific proportions from 53.6% (Honduras) to 82.3% (Uruguay). Attendance within the WHO window was higher (91.4%). Median ANC attendance was five visits, ranging from five (Honduras) to eight (Uruguay). Earlier ANC initiation was associated with higher visit counts. DISCUSSION: There is substantial potential for achieving high maternal RSV vaccine coverage in LAC, particularly per broader WHO vaccine recommendations. Where ANC begins later or visits are fewer, narrower vaccine-eligible windows may limit achievable coverage. Strengthening early ANC engagement and immunization counseling may increase vaccination opportunities.
引用
- Fleming JA, Colistro V, Knudson S, et al. Timing and frequency of antenatal care visits in relation to maternal respiratory syncytial virus vaccine opportunities in four Latin American countries. Vaccine. 2026. PMID: 42320380. doi:10.1016/j.vaccine.2026.128854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。